Polymyxin-like lipopeptide antibiotics of the future

未来的多粘菌素样脂肽抗生素

• 批准号: nhmrc : 1064896
• 负责人: Dr Tony Velkov
• 金额: $ 22.36万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/polymyxin-like-lipopeptide-antibiotics-future/455141
• 关键词: Polymyxin; like; lipopeptide; antibiotics; future

Polymyxins are now being clinically used as the ‘last-line’ therapy for infections caused by multidrug-resistant Gram-negative ‘superbugs’. For the first time our novel approach will interface chemistry and biology of the polymyxins with the purpose of creating a new generation of safer and more efficacious polymyxin antibiotics.

多粘菌素目前在临床上被用作由多重耐药革兰氏阴性“超级细菌”引起的感染的“最后一线”治疗。我们的新方法首次将多粘菌素的化学和生物学结合起来，目的是创造新一代更安全、更有效的多粘菌素抗生素。